|
REVB | Revelation Biosciences, Inc. |
|
|
REVB | Revelation Biosciences, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 1.25 |
| Leverage | 23.50% |
| Market Cap | $ 7.1m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -8.9m |
| Margin | -5759.17% |
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of immunological diagnostics and therapeutics for the prevention and treatment of disease. The company is headquartered in New York, New York.